Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 9Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Tuberous Sclerosis 2Vascular Malformations 1Triple Negative Breast Neoplasms 1Peutz-Jeghers Syndrome 1Perivascular Epithelioid Cell Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Malignant Solid Tumors 1Lymphangioma 1Lymphangioleiomyomatosis 1Leiomyoma 1Kaposiform Hemangioendothelioma 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Hemangioendothelioma 1Graft vs Host Disease 1Epilepsy 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumors 1

Interventions

Sorafenib 46lenvatinib 44apatinib 23sintilimab 22Fluorouracil 21camrelizumab 20Oxaliplatin 17Radiofrequency Ablation 16Radiosurgery 15Hepatectomy 15tislelizumab 14Leucovorin 14Radiotherapy 12Doxorubicin 12toripalimab 11Folfox protocol 10Bevacizumab 10Immune Checkpoint Inhibitors 9Epirubicin 9regorafenib 8Ethiodized Oil 8durvalumab 7donafenib 7anlotinib 7Neoadjuvant Therapy 7pembrolizumab 6entecavir 6Surgical Procedures, Operative 6Nivolumab 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Hepatocellular × Sirolimus × Clear all
NCT00554125 2007-11-06

Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria

Fudan University

Phase 3 Unknown
220 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡